We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High-Sensitivity Troponin Demonstrates Potential for Diagnosing Acute Coronary Syndrome

By LabMedica International staff writers
Posted on 24 Sep 2024

Chest pain is a common yet difficult symptom for general practitioners to assess, as it can stem from both serious and benign conditions. More...

Now, a new study has found that high-sensitivity troponin tests have the potential to diagnose acute coronary syndrome in primary care settings.

In the study, researchers at the Leiden University Medical Center (Leiden, The Netherlands) evaluated the effectiveness of various risk assessment tools, including clinical decision rules and troponin tests, in helping general practitioners rule out acute coronary syndrome in patients presenting with chest pain. They conducted a systematic review of studies involving adult patients with chest pain in primary care. The review included studies that assessed the diagnostic accuracy of different clinical decision rules and troponin point-of-care tests, both conventional and high-sensitivity, for identifying acute coronary syndrome, including heart attacks. These tools were compared to the unaided clinical judgment of general practitioners.

The review, which included 14 studies, revealed that some clinical decision rules without troponin improved safety. However, none consistently outperformed the unaided judgment of general practitioners in ruling out acute coronary syndrome. Conventional troponin tests, when used alone, did not meet the required diagnostic accuracy, making them less reliable in primary care. High-sensitivity troponin tests demonstrated the greatest diagnostic accuracy but require further prospective validation in primary care before being recommended for widespread use. While these tests show promise, they are not yet ready to replace clinical judgment or be used independently without additional validation.

Related Links:
Leiden University Medical Center


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Collection and Transport System
PurSafe Plus®
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i1000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.